These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12609964)

  • 1. Severe skin reaction to imatinib in a case of Philadelphia-positive acute lymphoblastic leukemia.
    Sanchez-Gonzalez B; Pascual-Ramirez JC; Fernandez-Abellan P; Belinchon-Romero I; Rivas C; Vegara-Aguilera G
    Blood; 2003 Mar; 101(6):2446. PubMed ID: 12609964
    [No Abstract]   [Full Text] [Related]  

  • 2. Prominent pleural effusion possibly due to imatinib mesylate in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ishii Y; Shoji N; Kimura Y; Ohyashiki K
    Intern Med; 2006; 45(5):339-40. PubMed ID: 16596010
    [No Abstract]   [Full Text] [Related]  

  • 3. Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Ronan Swords.
    Swords R
    Drugs; 2007; 67(17):2655-6. PubMed ID: 18034599
    [No Abstract]   [Full Text] [Related]  

  • 4. Tumor lysis syndrome after STI571 in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Dann EJ; Fineman R; Rowe JM
    J Clin Oncol; 2002 Jan; 20(1):354-5. PubMed ID: 11773197
    [No Abstract]   [Full Text] [Related]  

  • 5. Imatinib-induced Severe Hepatitis in a 9-Year-old Girl With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia.
    Suzuki R; Kobayashi C; Sakai A; Fukushima H; Tagawa M; Satomi K; Nanmoku T; Sumazaki R; Fukushima T
    J Pediatr Hematol Oncol; 2015 Aug; 37(6):e368-71. PubMed ID: 25929609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Joseph Brandwein.
    Brandwein J
    Drugs; 2007; 67(17):2655. PubMed ID: 18034600
    [No Abstract]   [Full Text] [Related]  

  • 7. Childhood Philadelphia-chromosome-positive B-lymphoblastic leukaemia.
    Thomas D
    Lancet Oncol; 2012 Sep; 13(9):860-2. PubMed ID: 22935232
    [No Abstract]   [Full Text] [Related]  

  • 8. Optimal central nervous system prophylaxis in Philadelphia chromosome-positive acute lymphoblastic leukemia: collateral damage in the imatinib era?
    Bassan R
    Leuk Lymphoma; 2011 Jul; 52(7):1164-5. PubMed ID: 21612380
    [No Abstract]   [Full Text] [Related]  

  • 9. Post-fracture excessive callus formation in a child on imatinib therapy.
    Ramzan M; Verma R; Chopra YR; Yadav SP
    Pediatr Blood Cancer; 2013 Dec; 60(12):2087-8. PubMed ID: 24038762
    [No Abstract]   [Full Text] [Related]  

  • 10. Imatinib for secondary Ph+ acute lymphoblastic leukemia induces response in concomitant GBM.
    De Vita S; De Matteis S; Laurenti L; Chiusolo P; Sorà F; Piccirillo N; Reddiconto G; Fiorini A; Leone G; Sica S
    Ann Oncol; 2006 Apr; 17(4):720-1. PubMed ID: 16263757
    [No Abstract]   [Full Text] [Related]  

  • 11. Imatinib: in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Cross SA; Lyseng-Williamson KA
    Drugs; 2007; 67(17):2645-54. PubMed ID: 18034597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Barbara Wassmann.
    Wassmann B
    Drugs; 2007; 67(17):2656. PubMed ID: 18034598
    [No Abstract]   [Full Text] [Related]  

  • 13. [Hypoprotidemia may explain imatinib intoxication in a patient with Philadelphia-positive acute lymphoblastic leukemia].
    Gaïes E; Trabelsi S; Sahnoun R; Salouage I; Jebabli N; Charfi R; Lakhal M; Hdiji S; Klouz A
    Therapie; 2013; 68(2):125-7. PubMed ID: 23773356
    [No Abstract]   [Full Text] [Related]  

  • 14. Bone marrow necrosis associated with the use of imatinib mesylate in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Matsue K; Takeuchi M; Koseki M; Uryu H
    Ann Hematol; 2006 Aug; 85(8):542-4. PubMed ID: 16570152
    [No Abstract]   [Full Text] [Related]  

  • 15. Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy.
    Patel SB; Gojo I; Tidwell ML; Sausville EA; Baer MR
    Leuk Lymphoma; 2011 Jul; 52(7):1211-4. PubMed ID: 21534873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diminished alpha2-plasmin inhibitor activity associated with the use of imatinib mesylate in patients with Philadelphia chromosome-positive haematologic cancer.
    Matsue K; Matsuo K; Fujiwara H; Iwama K; Hayama BY; Kimura S; Yamakura M; Takeuch M
    Thromb Haemost; 2009 Jun; 101(6):1170-1. PubMed ID: 19492163
    [No Abstract]   [Full Text] [Related]  

  • 17. Reversible cardiotoxicity with tyrosine kinase inhibitors.
    Francis J; Ahluwalia MS; Wetzler M; Wang E; Paplham P; Smiley S; McCarthy PL; Cohen IL; Spangenthal E; Battiwalla M
    Clin Adv Hematol Oncol; 2010 Feb; 8(2):128-32. PubMed ID: 20386534
    [No Abstract]   [Full Text] [Related]  

  • 18. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study.
    Schultz KR; Bowman WP; Aledo A; Slayton WB; Sather H; Devidas M; Wang C; Davies SM; Gaynon PS; Trigg M; Rutledge R; Burden L; Jorstad D; Carroll A; Heerema NA; Winick N; Borowitz MJ; Hunger SP; Carroll WL; Camitta B
    J Clin Oncol; 2009 Nov; 27(31):5175-81. PubMed ID: 19805687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ottmann OG; Wassmann B
    Hematology Am Soc Hematol Educ Program; 2005; ():118-22. PubMed ID: 16304368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response: Co-administration of cyclosporine A and imatinib among patients with Philadelphia chromosome-positive leukemias in the post-transplant setting.
    Atiq F; Broers AE; Andrews LM; Doorduijn JK; Koch BC; Van Gelder T; Versmissen J
    Eur J Clin Pharmacol; 2016 Dec; 72(12):1539-1540. PubMed ID: 27561268
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.